164 related articles for article (PubMed ID: 7915921)
1. Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease.
Cazzola M; Santangelo G; Piccolo A; Salzillo A; Matera MG; D'Amato G; Rossi F
Pulm Pharmacol; 1994 Apr; 7(2):103-7. PubMed ID: 7915921
[TBL] [Abstract][Full Text] [Related]
2. Effects of formoterol, salmeterol or oxitropium bromide on airway responses to salbutamol in COPD.
Cazzola M; Di Perna F; Noschese P; Vinciguerra A; Calderaro F; Girbino G; Matera MG
Eur Respir J; 1998 Jun; 11(6):1337-41. PubMed ID: 9657576
[TBL] [Abstract][Full Text] [Related]
3. Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD.
Cazzola M; Santus P; Di Marco F; Boveri B; Castagna F; Carlucci P; Matera MG; Centanni S
Respir Med; 2003 May; 97(5):453-7. PubMed ID: 12735659
[TBL] [Abstract][Full Text] [Related]
4. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study.
Cazzola M; Matera MG; Santangelo G; Vinciguerra A; Rossi F; D'Amato G
Respir Med; 1995 May; 89(5):357-62. PubMed ID: 7638371
[TBL] [Abstract][Full Text] [Related]
5. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists.
van der Woude HJ; Winter TH; Aalbers R
Thorax; 2001 Jul; 56(7):529-35. PubMed ID: 11413351
[TBL] [Abstract][Full Text] [Related]
6. Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action.
Celik G; Kayacan O; Beder S; Durmaz G
Respiration; 1999; 66(5):434-9. PubMed ID: 10516540
[TBL] [Abstract][Full Text] [Related]
7. A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol.
Lipworth BJ; Aziz I
J Allergy Clin Immunol; 1999 Jan; 103(1 Pt 1):88-92. PubMed ID: 9893190
[TBL] [Abstract][Full Text] [Related]
8. Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: results of a randomized, double-blind clinical study.
Kottakis J; Cioppa GD; Creemers J; Greefhorst L; Lecler V; Pistelli R; Overend T; Till D; Rapatz Gn; Le Gros V; Bouros D; Siafakas N
Can Respir J; 2002; 9(2):107-15. PubMed ID: 11972164
[TBL] [Abstract][Full Text] [Related]
9. Long-acting beta2-agonists for chronic obstructive pulmonary disease.
Appleton S; Smith B; Veale A; Bara A
Cochrane Database Syst Rev; 2000; (2):CD001104. PubMed ID: 10796594
[TBL] [Abstract][Full Text] [Related]
10. Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease.
Appleton S; Poole P; Smith B; Veale A; Lasserson TJ; Chan MM
Cochrane Database Syst Rev; 2006 Jul; (3):CD001104. PubMed ID: 16855959
[TBL] [Abstract][Full Text] [Related]
11. Formoterol 12 microg BID administered via single-dose dry powder inhaler in adults with asthma suboptimally controlled with salmeterol or on-demand salbutamol: a multicenter, randomized, open-label, parallel-group study.
Brambilla C; Le Gros V; Bourdeix I;
Clin Ther; 2003 Jul; 25(7):2022-36. PubMed ID: 12946548
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the bronchodilating effects of inhaled formoterol, salmeterol and salbutamol in asthmatic patients.
Grembiale RD; Pelaia G; Naty S; Vatrella A; Tranfa CM; Marsico SA
Pulm Pharmacol Ther; 2002; 15(5):463-6. PubMed ID: 12406669
[TBL] [Abstract][Full Text] [Related]
13. Profiles of measured and perceived bronchodilation. A placebo-controlled cross-over trial comparing formoterol and salmeterol in moderate persistent asthma.
Schermer TR; Hoff WJ; Greefhorst AP; Creemers JP; Sips AP; Westbroek J; van Herwaarden CL
Pulm Pharmacol Ther; 2004; 17(4):205-12. PubMed ID: 15219265
[TBL] [Abstract][Full Text] [Related]
14. Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk).
Benhamou D; Cuvelier A; Muir JF; Leclerc V; Le Gros V; Kottakis J; Bourdeix I
Respir Med; 2001 Oct; 95(10):817-21. PubMed ID: 11601748
[TBL] [Abstract][Full Text] [Related]
15. Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease.
Cazzola M; D'Amato M; Califano C; Di Perna F; Calderaro E; Matera MG; D'Amato G
Clin Ther; 2002 Apr; 24(4):595-604. PubMed ID: 12017404
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the efficacy of formoterol and salmeterol in patients with reversible obstructive airway disease: a multicenter, randomized, open-label trial.
Condemi JJ
Clin Ther; 2001 Sep; 23(9):1529-41. PubMed ID: 11589265
[TBL] [Abstract][Full Text] [Related]
17. Early reversibility to salbutamol does not always predict bronchodilation after salmeterol in stable chronic obstructive pulmonary disease.
Cazzola M; Vinciguerra A; Di Perna F; Matera MG
Respir Med; 1998 Aug; 92(8):1012-6. PubMed ID: 9893768
[TBL] [Abstract][Full Text] [Related]
18. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency.
Palmqvist M; Persson G; Lazer L; Rosenborg J; Larsson P; Lötvall J
Eur Respir J; 1997 Nov; 10(11):2484-9. PubMed ID: 9426083
[TBL] [Abstract][Full Text] [Related]
19. Combined corticosteroid and longacting beta-agonist in one inhaler for chronic obstructive pulmonary disease.
Nannini L; Lasserson TJ; Poole P
Cochrane Database Syst Rev; 2003; (4):CD003794. PubMed ID: 14583994
[TBL] [Abstract][Full Text] [Related]
20. Effects of prior treatment with salmeterol and formoterol on airway and systemic beta 2 responses to fenoterol.
Grove A; Lipworth BJ
Thorax; 1996 Jun; 51(6):585-9. PubMed ID: 8693438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]